![Pinterest](https://pinterest.com/pin/create/button/?url=https://xperttimes.com/solar-pharma-posts-16-5-rise-in-q3-web-revenue-declares-dividend-of-rs-8-50-share/&media=https://xperttimes.com/wp-content/uploads/2024/01/Sun-Pharma-posts-165-rise-in-Q3-net-profit-declares.jpg&description=[ad_1] MUMBAI: Solar Pharmaceutical Industries Ltd on Wednesday reported a 16.52 per cent rise in web revenue at Rs 2, 523.75 crore for the October-December quarter of the present monetary yr on the again of robust gross sales within the home and US markets. The corporate had reported a web revenue of Rs 2, 166.01 crore in the identical interval of the earlier fiscal. The pharma main’s board has declared an interim dividend of Rs 8.50 per share for 2023-24, up from Rs 7.50 per share interim dividend for the earlier yr. The corporate’s income from operations rose 10 per cent to Rs 12, 381 crore within the December quarter. Solar Prescribed drugs Managing Director Dilip Shanghvi stated, "We're happy by our continued broad-based progress, together with in world specialty. We're keenly trying ahead to EMA submitting of Nidlegy within the coming months. As soon as authorised, Nidlegy will considerably broaden our onco-derm franchise in Europe." The corporate’s share value shot up 4.88 per cent after the outcomes to cross a one-year excessive at Rs 1, 438.50. [ad_2]){kind=link}
MUMBAI: Solar Pharmaceutical Industries Ltd on Wednesday reported a 16.52 per cent rise in web revenue at Rs 2, 523.75 crore for the October-December quarter of the present monetary yr on the again of robust gross sales within the home and US markets.
The corporate had reported a web revenue of Rs 2, 166.01 crore in the identical interval of the earlier fiscal.
The pharma main’s board has declared an interim dividend of Rs 8.50 per share for 2023-24, up from Rs 7.50 per share interim dividend for the earlier yr.
The corporate’s income from operations rose 10 per cent to Rs 12, 381 crore within the December quarter.
Solar Prescribed drugs Managing Director Dilip Shanghvi stated, “We’re happy by our continued broad-based progress, together with in world specialty. We’re keenly trying ahead to EMA submitting of Nidlegy within the coming months. As soon as authorised, Nidlegy will considerably broaden our onco-derm franchise in Europe.”
The corporate’s share value shot up 4.88 per cent after the outcomes to cross a one-year excessive at Rs 1, 438.50.